Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Hikmat Abdel-Razeq & Lina Marei. (2011) Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics: Targets and Therapy 5, pages 87-94.
Read now
Read now
Howard A Burris$suffix/text()$suffix/text(). (2011) Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opinion on Biological Therapy 11:6, pages 807-819.
Read now
Read now
Articles from other publishers (49)
Elizabeth Garcia, Ismat Luna, Kaya L. Persad, Kate Agopsowicz, David A. Jay, Frederick G. West, Mary M. Hitt & Sujata Persad. (2021) Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition. Scientific Reports 11:1.
Crossref
Crossref
Katia Khoury, Filipa Lynce, Ana Barac, Xue Geng, Chau Dang, Anthony F. Yu, Karen L. Smith, Christopher Gallagher, Paula R. Pohlmann, Raquel Nunes, Pia Herbolsheimer, Robert Warren, Monvadi B. Srichai, Mark Hofmeyer, Federico Asch, Ming Tan, Claudine Isaacs & Sandra M. Swain. (2021) Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Research and Treatment 185:3, pages 863-868.
Crossref
Crossref
Doaa Abd Alghafar, Ibrahim Younos, Khalid Al Baimani, Dawood Al-Salhi, Adil Al-Riyami, Syed Rizvi & Niamh E Buckley. (2020) Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman. Journal of Oncology Pharmacy Practice, pages 107815522091988.
Crossref
Crossref
Hans-Christian Kolberg, Marco Colleoni, Georgia Savva Demetriou, Patricia Santi, Hans Tesch, Yasuhiro Fujiwara, Zorica Tomasevic & Vladimir Hanes. (2020) Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. Drug Safety 43:3, pages 233-242.
Crossref
Crossref
Konstantin Dobrenkov & Nai-Kong V. Cheung. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
486
499.e8
.
Marco Mazzotta, Eriseld Krasniqi, Giacomo Barchiesi, Laura Pizzuti, Federica Tomao, Maddalena Barba & Patrizia Vici. (2019) Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer. Journal of Clinical Medicine 8:2, pages 254.
Crossref
Crossref
Sonia Pernas, Romualdo Barroso‐Sousa & Sara M. Tolaney. (2018) Optimal treatment of early stage HER2‐positive breast cancer. Cancer 124:23, pages 4455-4466.
Crossref
Crossref
Elisa Pierpaoli, Gaetano Fiorillo, Paolo Lombardi, Carmela Salvatore, Cristina Geroni, Francesco Piacenza & Mauro Provinciali. (2018) Antitumor activity of NAX060: A novel semisynthetic berberine derivative in breast cancer cells. BioFactors 44:5, pages 443-452.
Crossref
Crossref
Jung Yoon Choi, Eun Young Cho, Yoon Ji Choi, Jeong Hyeon Lee, Seung Pil Jung, Kyu Ran Cho, Chul Yong Kim, Yeul Hong Kim & Kyong Hwa Park. (2018) Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database. Breast Cancer Research and Treatment 171:1, pages 181-188.
Crossref
Crossref
Vivian Y. Chang & Jessica J. Wang. (2018) Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity. Current Oncology Reports 20:7.
Crossref
Crossref
Adriana D. Oprea, Raymond R. Russell, Kerry S. Russell & Maysa Abu-Khalaf. (2017) Chemotherapy Agents With Known Cardiovascular Side Effects and Their Anesthetic Implications. Journal of Cardiothoracic and Vascular Anesthesia 31:6, pages 2206-2226.
Crossref
Crossref
Grace H. Tang, Sergio A. Acuna, Laura Sevick, Andrew T. Yan & Christine Brezden-Masley. (2017) Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single “real-world” setting. Medical Oncology 34:9.
Crossref
Crossref
T. Genevée & B. Lortal. (2017) Données en vie réelle de l’utilisation du trastuzumab IV dans le carcinome mammaire métastatique HER2-positifReal-life datas of intravenous trastuzumab use in metastatic breast cancer HER2-positive. Oncologie 19:7-8, pages 247-255.
Crossref
Crossref
LR Grazziotin & PD Picon. (2016) Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer. Journal of Oncology Pharmacy Practice 23:4, pages 264-272.
Crossref
Crossref
J. Gavila, M. Á. Seguí, L. Calvo, T. López, J. J. Alonso, M. Farto & R. Sánchez-de la Rosa. (2016) Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study. Clinical and Translational Oncology 19:1, pages 91-104.
Crossref
Crossref
Christine C. Davis, Amelia Zelnak, J. William Eley, Daniel A. Goldstein, Jeffrey M. Switchenko & Trevor McKibbin. (2016) Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab. Annals of Pharmacotherapy 50:9, pages 712-717.
Crossref
Crossref
Sherry J. Morgan & Chandikumar S. Elangbam. 2016. Drug Discovery Toxicology. Drug Discovery Toxicology
261
297
.
Hart A. Goldhar, Andrew T. Yan, Dennis T. Ko, Craig C. Earle, George A. Tomlinson, Maureen E. Trudeau, Murray D. Krahn, Monika K. Krzyzanowska, Raveen S. Pal, Christine Brezden-Masley, Scott Gavura, Kelly Lien & Kelvin K. W. Chan. (2015) The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. Journal of the National Cancer Institute 108:1, pages djv301.
Crossref
Crossref
Hye-young Wang, Sunghyun Kim, Sangjung Park, Seungil Kim, Dongju Jung, Kwang Hwa Park & Hyeyoung Lee. (2014) Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples. Experimental and Molecular Pathology 97:3, pages 368-374.
Crossref
Crossref
Cristina SauraJose A. Garcia-SaenzBinghe XuWael HarbRebecca MorooseTimothy PluardJavier CortésCorinne KigerCaroline GermaKongming WangMiguel MartinJosé BaselgaSung-Bae Kim. (2014) Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Journal of Clinical Oncology 32:32, pages 3626-3633.
Crossref
Crossref
Sibo Tian, Kim M. Hirshfield, Salma K. Jabbour, Deborah Toppmeyer, Bruce G. Haffty, Atif J. Khan & Sharad Goyal. (2014) Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients. Frontiers in Oncology 4.
Crossref
Crossref
Adedayo A. Onitilo, Jessica M. Engel & Rachel V. Stankowski. (2014) Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Therapeutic Advances in Drug Safety 5:4, pages 154-166.
Crossref
Crossref
Kaitlin B. Baron, Jennifer R. Brown, Brian L. Heiss, Joanne Marshall, Nancy Tait, Katherine H.R. Tkaczuk & Stephen S. Gottlieb. (2014) Trastuzumab-Induced Cardiomyopathy: Incidence and Associated Risk Factors in an Inner-City Population. Journal of Cardiac Failure 20:8, pages 555-559.
Crossref
Crossref
Tanja Marinko, Jure Dolenc & Cvetka Bilban-Jakopin. (2014) Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. Radiology and Oncology 48:2, pages 105-112.
Crossref
Crossref
Véronique Diéras & Thomas Bachelot. (2013) The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. Targeted Oncology 9:2, pages 111-122.
Crossref
Crossref
James P. Carroll, Melinda M. Protani, Linda Nguyen, Matthew E. Cheng, Mike Fay, Mohamed Saleem, Praga S. Pillay, Euan Walpole & Jennifer H. Martin. (2014) Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. Medical Oncology 31:4.
Crossref
Crossref
Nai-Kong V. Cheung. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
508
518.e7
.
Eugenia Ch Yiannakopoulou. 2014. Omics Approaches in Breast Cancer. Omics Approaches in Breast Cancer
483
498
.
Elisa Pierpaoli, Andrea G. Arcamone, Franco Buzzetti, Paolo Lombardi, Carmela Salvatore & Mauro Provinciali. (2013) Antitumor effect of novel berberine derivatives in breast cancer cells. BioFactors 39:6, pages 672-679.
Crossref
Crossref
Brett DobleAnthony Harris, David M Thomas, Stephen Fox & Paula Lorgelly. (2013) Multiomics medicine in oncology: assessing effectiveness, cost–effectiveness and future research priorities for the molecularly unique individual. Pharmacogenomics 14:12, pages 1405-1417.
Crossref
Crossref
Louis P. GarrisonJr.Jr., Deepa Lalla, Melissa Brammer, Joseph B. Babigumira, Bruce Wang & Edith A. Perez. (2013) Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status. Cancer 119:17, pages 3113-3122.
Crossref
Crossref
Brian R. Berridge, Peter Hoffmann, James R. Turk, Frank Sellke, Gary Gintant, Gerald Hirkaler, Kevin Dreher, A. Eric Schultze, Dana Walker, Nick Edmunds, Wendy Halpern, James Falls, Marty Sanders & Syril D. Pettit. (2013) Integrated and translational nonclinical in vivo cardiovascular risk assessment: Gaps and opportunities. Regulatory Toxicology and Pharmacology 65:1, pages 38-46.
Crossref
Crossref
A. Awada, L. Dirix, L. Manso Sanchez, B. Xu, T. Luu, V. Diéras, D.L. Hershman, V. Agrapart, R. Ananthakrishnan & E. Staroslawska. (2013) Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Annals of Oncology 24:1, pages 109-116.
Crossref
Crossref
Anthony Gonçalves, Olivier Trédan, Christian Villanueva & Charles Dumontet. (2012) Les anticorps conjugués en oncologie : du concept au trastuzumab emtansine (T-DM1). Bulletin du Cancer 99:12, pages 1183-1191.
Crossref
Crossref
Andrew G Polson & Reina N Fuji. (2012) The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients. British Journal of Pharmacology 166:5, pages 1600-1602.
Crossref
Crossref
Adedayo A. Onitilo, Jessica M. Engel, Rachel V. Stankowski, Hong Liang, Richard L. Berg & Suhail A. R. Doi. (2012) High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Research and Treatment 134:1, pages 291-298.
Crossref
Crossref
Mina Mhallem Gziri, Frédéric Amant, Frédéric Debiève, Kristel Van Calsteren, Luc De Catte & Luc Mertens. (2012) Effects of chemotherapy during pregnancy on the maternal and fetal heart. Prenatal Diagnosis 32:7, pages 614-619.
Crossref
Crossref
Laurence M. Wood, Zhen-Kun Pan, Matthew M. Seavey, Geetha Muthukumaran & Yvonne Paterson. (2011) The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunology, Immunotherapy 61:5, pages 689-700.
Crossref
Crossref
J. Huober, P.A. Fasching, M. Barsoum, L. Petruzelka, D. Wallwiener, C. Thomssen, T. Reimer, S. Paepke, H.A. Azim, V. Ragosch, E. Kubista, A.K. Baumgärtner, M.W. Beckmann, C. May, I. Nimmrich & N. Harbeck. (2012) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial. The Breast 21:1, pages 27-33.
Crossref
Crossref
Maximilian Niyazi, Cornelius Maihoefer, Mechthild Krause, Claus Rödel, Wilfried Budach & Claus Belka. (2011) Radiotherapy and "new" drugs-new side effects?. Radiation Oncology 6:1.
Crossref
Crossref
Nasser Ghaly Yousif & Fadhil G Al-amran. (2011) Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC Cardiovascular Disorders 11:1.
Crossref
Crossref
Patricia M. LoRusso, Denise Weiss, Ellie Guardino, Sandhya Girish & Mark X. Sliwkowski. (2011) Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer. Clinical Cancer Research 17:20, pages 6437-6447.
Crossref
Crossref
Teresa Alonso Gordoa, José Ángel García-Sáenz, Juan Francisco Rodríguez Moreno, Francisco José Hernández Pérez & Eduardo Díaz-Rubio. (2011) Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome?. Clinical and Translational Oncology 13:7, pages 451-459.
Crossref
Crossref
Henry KrumMichael V JelinekSimon StewartAndrew SindoneJohn J Atherton. (2011) 2011 Update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Medical Journal of Australia 194:8, pages 405-409.
Crossref
Crossref
Brian B. Hasinoff & Daywin Patel. (2010) The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicology and Applied Pharmacology 249:2, pages 132-139.
Crossref
Crossref
Lee W. Jones, Jeffrey Peppercorn, Jessica M. Scott & Claudio Battaglini. (2010) Erratum to: Exercise Therapy in the Management of Solid Tumors. Current Treatment Options in Oncology 11:3-4, pages 73-86.
Crossref
Crossref
Jeffrey S. Ross. (2010) Human Epidermal Growth Factor Receptor 2 Testing in 2010: Does Chromosome 17 Centromere Copy Number Make Any Difference?. Journal of Clinical Oncology 28:28, pages 4293-4295.
Crossref
Crossref
Jeffrey S. Ross. (2010) Saving Lives With Accurate HER2 Testing. American Journal of Clinical Pathology 134:2, pages 183-184.
Crossref
Crossref
Lee W. Jones, Jeffrey Peppercorn, Jessica M. Scott & Claudio Battaglini. (2010) Exercise Therapy in the Management of Solid Tumors. Current Treatment Options in Oncology 11:1-2, pages 45-58.
Crossref
Crossref